Sort
261,768 grants matching “gene therapy”
Immunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) Disease
$1,670,904Irini Sereti · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Blood and Marrow Transplant Clinical Trials Network Data Coordinating Center
$1,670,546Mary M Horowitz · Medical College Of Wisconsin · U24 · FY2019 · HL
Adeno-associated Virus Biology And Utilization For Gene Transfer
$1,670,313John A Chiorini · National Institute Of Dental & Craniofacial Research · Z01 · FY2008 · DE
PARKINSON'S DISEASE RESEARCH CENTER AT COLUMBIA
$1,670,256Columbia University Health Sciences · P50 · FY2003 · NS
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
$1,670,008Peter G Stock · University Of California, San Francisco · U01 · FY2015 · AI
Program Project: GENE MUTATION AND RESCUE IN HUMAN DIAPHRAGMATIC HERNIA
$1,670,002Patricia K Donahoe · Massachusetts General Hospital · P01 · FY2012 · HD
Novel Mechanisms and Therapies in Heart Failure
$1,669,698Howard A Rockman · Duke University · P01 · FY2016 · HL
Eosinophils and Eosinophil Activation in the Pathogenesis of Human Disease
$1,669,694Amy Klion · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Novel Mechanisms and Therapies in Heart Failure
$1,669,496Howard A Rockman · Duke University · P01 · FY2017 · HL
Mitigation of the Catecholamine Surge in Severely Burned Patients
$1,669,435David N Herndon · University Of Texas Med Br Galveston · P50 · FY2013 · GM
Molecular Analysis Of Retroviral Genes And Their Products
$1,669,386Klaus Strebel · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Clinical evaluation of BMS-984923 metabolism.
$1,669,100Timothy R Siegert · Allyx Therapeutics Inc. · SB1 · FY2025 · AG
Novel Mechanisms and Therapies in Heart Failure
$1,669,076Howard A Rockman · Duke University · P01 · FY2019 · HL
Disease mechanism and therapies for retinal degeneration
$1,668,911Tiansen Li · National Eye Institute · ZIA · FY2015 · EY
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,668,869Mark Connors · Niaid Extramural Activities · Z01 · FY2007 · AI
SBIR Phase II: Clinical scale and testing of the first virus-free precision gene edited cell therapy for veterinary oncology
$1,668,708Wesley A Wierson · Lifengine Animal Health Laboratories Incorporated · · FY2023 · TIP
Information Signaling Pathways in the Vasculature
$1,668,704Dudley K. Strickland · University Of Maryland Baltimore · P01 · FY2007 · HL
NINDS Cooperative Program in Translational Research
$1,668,536Mary P Stenzel-Poore · Oregon Health & Science University · U01 · FY2010 · NS
Repurposing an EU Therapeutic for Hemoglobinopathies
$1,668,330Sharie Haugabook · National Center For Advancing Translational Sciences · ZIA · FY2023 · TR
The Impact of DNA Damage Repair Abnormalities in Prostate Cancer
$1,668,159Kenneth Offit · Sloan-Kettering Inst Can Research · P01 · FY2022 · CA
The Impact of DNA Damage Repair Abnormalities in Prostate Cancer
$1,668,159Kenneth Offit · Sloan-Kettering Inst Can Research · P01 · FY2023 · CA
Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy
$1,668,155Stephen H. Embury · Vanguard Therapeutics, Inc. · R44 · FY2016 · HL
Etiology of Alkylator-Induced Myeloid Leukemia
$1,667,989Michelle M Le Beau · University Of Chicago · P01 · FY2008 · CA
Mucosal Immune Defense Mechanisms of the Urinary Bladder
$1,667,884Marco Colonna · Washington University · U01 · FY2017 · AI
Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution
$1,667,876Chang C Liu · University Of California-Irvine · R01 · FY2023 · CA